A Phase 3 interventional study of Nintedanib in Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim. Completed at 121 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing nintedanib in Lung Diseases, Interstitial — 1 open to participants now, 1 under way, 1 of them phase 3. nintedanib · Lung Diseases, Interstitial.
Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 3, and was the 3rd registered.
682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.
Browse Lung Diseases, Interstitial studies →1 of the 11 studies testing nintedanib in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · Sites in Poland
Ages 18–74
By country, each count listing its studies:
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 173 Lung Diseases, Interstitial studies recruiting now, 108 (62%) set no upper age limit and 25 (14%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 2 started in 2019.
This study's enrollment of 435 is above the median of 60 across 386 interventional studies indexed under Lung Diseases, Interstitial.
Median enrollment 81 across the 11 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 6 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim: 4 open now, 6 under way, 4 of them phase 3. Of 16 finished, 11 (69%) have results posted.
Among the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2019, is one of 11 in phase 3, and was the 3rd registered.
Boehringer Ingelheim’s Lung Diseases, Interstitial studies by the year they started, since 2017.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, from their registry updates:
Among Boehringer Ingelheim’s 24 in Lung Diseases, Interstitial:
This tab as a report to print or save as PDF → With an account.
The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue trial medication in) the phase III parent trial, INBUILD® (trial 1199.247).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients taking 150 milligram (mg) bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib 150 mg bid in this extension trial. Patients taking 100 mg bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib in this extension trial either at 100 mg bid or at an increased dose of 150 mg bid at the discretion of the investigator orally as soft gelatine capsule, twice daily (bid), together with a glass of water (\~250 mL), in a dose interval of 12 hours. With an optional dose reduction to 100 mg bid temporarily or permanently to manage adverse events (AEs). The treatment had a duration of 96 weeks or until nintedanib was made available to the patients outside of the clinical trial. Treatment was stopped if any reason for withdrawal was met.
Drug: Nintedanib
Bid
Number of Participants With Any Adverse Events
Number of participants with adverse events over the course of the extension trial, AEs defined as any untoward medical occurrence in a patient administered with the investigational product and which does not necessarily have to have a causal relationship with this treatment.
Time frame: From first nintedanib intake until last nintedanib intake + 28 days of Residual effect period (REP), up to 1195 days.
A phase III, open label, extension trial. The study aimed to evaluate the long-term tolerability and safety of oral nintedanib treatment in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have completed (and did not prematurely discontinue trial medication in) the phase III parent trial, 1199.247 (INBUILD®) NCT02999178.
| Milestone | Nintedanib |
|---|---|
| Started | 435 |
| Treated | 434 |
| Completed | 224 |
| Not completed | 211 |
| Withdrew: Other than listed | 23 |
| Withdrew: Withdrawal by subject | 37 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Protocol deviation | 1 |
| Withdrew: Adverse event | 146 |
| Withdrew: Not treated | 1 |
Number of participants with adverse events over the course of the extension trial, AEs defined as any untoward medical occurrence in a patient administered with the investigational product and which does not necessarily have to have a causal relationship with this treatment.
| Participants | Nintedanib |
|---|---|
| Number of Participants With Any Adverse Events | 417 |
Collected over From first nintedanib intake until last nintedanib intake + 28 days of Residual effect period (REP), up to 1195 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib | 83/434 (19.1%) | 234/434 (53.9%) | 371/434 (85.5%) |
| Event | Nintedanib |
|---|---|
| PneumoniaInfections and infestations | 36/434 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 35/434 |
| Pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 20/434 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 17/434 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 15/434 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 14/434 |
| COVID-19Infections and infestations | 12/434 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 12/434 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 9/434 |
| Atrial fibrillationCardiac disorders | 7/434 |
| Event | Nintedanib |
|---|---|
| DiarrhoeaGastrointestinal disorders | 256/434 |
| NauseaGastrointestinal disorders | 75/434 |
| CoughRespiratory, thoracic and mediastinal disorders | 73/434 |
| Weight decreasedInvestigations | 69/434 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 61/434 |
| VomitingGastrointestinal disorders | 54/434 |
| BronchitisInfections and infestations | 48/434 |
| Decreased appetiteMetabolism and nutrition disorders | 45/434 |
| Alanine aminotransferase increasedInvestigations | 43/434 |
| NasopharyngitisInfections and infestations | 38/434 |
Treated Set (TS): This set included all patients who were dispensed trial medication (nintedanib) and were documented to have taken at least 1 dose of open-label trial medication (nintedanib).
| Age, Continuous(Years) | Nintedanib |
|---|---|
| Mean | 65.9 ± 9.9 |
| Sex: Female, Male(Participants) | Nintedanib |
|---|---|
| Female | 211 |
| Male | 223 |
| Ethnicity (NIH/OMB)(Participants) | Nintedanib |
|---|---|
| Hispanic or Latino | 65 |
| Not Hispanic or Latino | 328 |
| Unknown or Not Reported | 41 |
| Race (NIH/OMB)(Participants) | Nintedanib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 108 |
| Native Hawaiian or Other Pacific Islander | 1 |
| Black or African American | 4 |
| White | 279 |
| More than one race | 1 |
| Unknown or Not Reported | 41 |
Showing the first 100 of 121 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Once the criteria in section 'time frame frame' are fulfilled , researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Apr 2019 to primary completion in Aug 2022, 40 months.
Results were first posted in Sep 2023, 1 year after primary completion.
Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's 40 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib